SciELO - Scientific Electronic Library Online

 
vol.30 suppl.5Correlación entre evaluación por el sistema APACHE-II, evolución de función renal y sobrevida en pacientes críticosRegresión del segmento ST: Indicador pronóstico de reperfusión en el infarto agudo del miocardio índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Medicina Militar

versión On-line ISSN 1561-3046

Resumen

PADRON SANCHEZ, Armando; BRAVO PEREZ, Rigoberto; PUGA TORRES, Mario Santiago  y  JOANES FIOL, Javier. Door-drug interval. Rev Cub Med Mil [online]. 2001, vol.30, suppl.5, pp. 41-46. ISSN 1561-3046.

Sixty-seven patients with acute myocardial infarction were studied, who had been applied a streptokinase-based thrombolytic treatment in the Emergency service of “Dr Luis Díaz Soto” Higher Institute of Military Medicine. The sample was divided into 2 groups: those who receive thrombolytics within 6 hours of the onset of symptoms (group A) and those who received them after 6 hours (group B). This variable was called door-drug interval. The objective was to define how the door-drug interval influences on the course and complication of the acute myocardial infarction. The group A patients had less mechanical complications and heart failure, more supraventricular arrhythmias and the difference of ST segment regression was higher, but their progression was more favorable than that of the group B patients. It is concluded that the use of thrombolytic therapy in the acute myocardial infarction should begin as soon as possible to reduce risks of future complications.

Palabras clave : MYOCARDIAL INFARCTION [drug therapy]; FIBRINOLYTIC AGENTS [therapeutic use]; INTENSIVE CARE UNITS.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License